Cardio Suite to reportedly provide clinicians with artificial intelligence technology to help fight cardiovascular disease.
ConcertAI’s TeraRecon, a clinical AI SaaS company, broke the news that its Eureka Clinical AI platform's Cardio Suite now provides clinicians with the artificial intelligence and deep learning technology necessary to help identify, treat, and manage cardiovascular disease.
"The Cardio Suite represents our second installment of dedicated care area suites following the launch of the Neuro Suite earlier this year," said Dan McSweeney, President, TeraRecon. "We are committed to supporting cardiologists and clinicians by bringing novel AI powered solutions, such as our Cardio Suite, forward to more efficiently help physicians screen and diagnose cardiac disease patients so that appropriate treatments can be delivered."
Reference: ConcertAI's TeraRecon Adds Cardio Suite to its Eureka Clinical AI Platform. PR Newswire. August 30, 2023. Accessed September 5, 2023. https://www.prnewswire.com/news-releases/concertais-terarecon-adds-cardio-suite-to-its-eureka-clinical-ai-platform-301912876.html
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.